Transplantatie en cellulaire therapie

Pediatric subjects with chronic Graft Versus Host
Disease.
                                                                    Ibrutinib (PCYC-1146-IM)


Patients less than 18 years of age with histologically            
BIANCA
confirmed B-cell NHL who have relapsed after
one or more prior therapies or are primary refractory.
 


Pediatric HSCT recipients transplanted from a                       Tracing HSCs after transplantation
sibling donor, with >95% donor chimerism and
without major HSCT-related complications.


Tisagenlecleucel (Kymriah
®) as standard of care                  Tisagenlecleucel


Patients 12-65 years of age with a diagnosis of                      NiCord III       
hematological malignancy who are candidates
for unrelated cord blood transplantation, with 
qualifying HLA-matched UCB units with sufficient 
pre-cryopreserved total nucleated cell dose and 
CD34+ cell dose (see protocol for further specs)


Pediatric patients (0-18 years old) receiving a                        PARACHUTE
non-T-cell depleted allogeneic hematopoietic                        (gesloten voor inclusie)
cell transplantation with Thymoglobulin in the
conditioning regimen as standard of care.